ARK Genomic Revolution ETF ARKG

Medalist Rating as of | See ARK Investment Hub

Morningstar’s Analysis ARKG

Will ARKG outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

ARK Genomic Revolution ETF holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings ARKG

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 62.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Twist Bioscience Corp

10.30 232M
Healthcare

10x Genomics Inc Ordinary Shares - Class A

10.02 226M
Healthcare

Tempus AI Inc Class A common stock

8.93 201M
Healthcare

CRISPR Therapeutics AG

5.24 118M
Healthcare

Absci Corp

5.06 114M
Healthcare

Personalis Inc

4.88 110M
Healthcare

Guardant Health Inc

4.61 104M
Healthcare

Natera Inc

4.53 102M
Healthcare

Illumina Inc

4.49 101M
Healthcare

CareDx Inc

4.34 98M
Healthcare

Sponsor Center